Smith+Nephew Launched Cartilage Repair Implant in Europe
The company introduced its aragonite-based medical device following a successful US release in 2024.
Updated on Oct. 6, 2026 in Arthritis
Live Poll
Do you trust new medical implants more when they are backed by multi-year clinical trial evidence?
Smith+Nephew has launched its CARTIHEAL AGILI-C cartilage repair implant across several European markets. The device is designed to treat cartilage defects in patients with or without osteoarthritis by repairing cartilage and restoring bone.
Why it matters
This expansion provides surgeons with a new, clinically proven treatment option for cartilage damage. The implant aims to improve patient outcomes by leveraging a biphasic scaffold composed of naturally occurring calcium carbonate.
A multicenter randomized controlled trial confirmed superior outcomes over a 60-month follow-up period. The device utilizes a biphasic scaffold derived from naturally occurring calcium carbonate.
The players
Smith+Nephew
This global medical technology company employs 17,000 people and reported $6.2 billion in annual sales in 2025.
ICRS Summit
This professional medical gathering in Portugal serves as a platform for experts to discuss advancements in cartilage repair.
The details
The CARTIHEAL AGILI-C implant utilizes a biphasic scaffold composed of naturally occurring aragonite to facilitate joint repair. Surgeons perform specialized procedures to deliver the device to patients suffering from cartilage defects.
Timeline
Smith+Nephew introduced the CARTIHEAL implant in the US in 2024.
The ICRS Summit will take place in Porto, Portugal, from October 8-10, 2026.
Health Landscape
This product launch follows a pattern of clinical adoption for cartilage repair technologies set by the International Cartilage Regeneration and Joint Preservation Society research initiatives. The move marks a shift toward utilizing naturally occurring calcium carbonate structures for orthopedic reconstruction.
Patients suffering from cartilage defects may soon have access to a clinically proven treatment option that provides long-term pain relief and functional improvement. Individuals should consult with their orthopedic surgeons to determine if this new procedure is suitable for their specific condition.
The takeaway
The introduction of this aragonite-based implant highlights a growing shift toward non-invasive biological scaffolds in orthopedics. Patients should prioritize discussng new clinical options with medical specialists as these technologies become available in their region.
What happens next
Smith+Nephew will showcase the CARTIHEAL AGILI-C implant at the ICRS Summit held in Porto, Portugal, from October 8-10, 2026.
Further reading
For more information on the latest breakthroughs in joint care, visit the Arthritis section.
Live Poll
Do you trust new medical implants more when they are backed by multi-year clinical trial evidence?
